Demir Karboksimaltoz Tedavisi Sonrası Hipofosfatemi Sıklığı: Tek Merkez Deneyimi

Amaç: Demir karboksimaltoz (DKM) infüzyonu sonrası hipofosfatemi sıklığını ve hipofosfatemiye etki eden faktörleri değerlendirmek amaçlanmıştır. Gereç ve Yöntem: Demir eksikliği anemisi (DEA) nedeniyle DKM tedavisi alan 92 hasta çalışmaya alındı. DKM öncesi ve sonrası fosfor, kalsiyum, magnezyum, 25-hidroksi vitamin D, parathormon seviyeleri dosya bilgilerinden kaydedildi. Hipofosfatemi serum fosfor düzeyinin

Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience

Aim: The aim of this study was to evaluate the incidence of hypophosphatemia after ferric carboxymaltose (FCM) infusion and the factors affectinghypophosphatemia.Materials and Methods: Ninety-two patients who received FCM treatment for iron deficiency anemia (IDA) were included in the study. Phosphorus,calcium, magnesium, 25-hydroxy vitamin D, and parathyroid hormone levels before and after FCM infusion were obtained from the medical records.Hypophosphatemia was defined as serum phosphorus level of

PDF

___

1. World Health Organization. Iron Deficiency Anaemia Assessment, Prevention, and Control. A guide for programme managers. Switzerland: World Health Organization; 2001.
2. World Health Organization. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015.
3. Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, Haya-Palazuelos J, Ciria-Recasens M, Manasanch J, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013;29:291-303.
4. Gereklioglu C, Asma S, Korur A, Erdogan F, Kut A. Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pak J Med Sci. 2016;32:604-7.
5. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung. 2010;60:399-412.
6. Emrich IE, Lizzi F, Siegel JD, Seiler-Mussler S, Ukena C, Kaddu-Mulindwa D, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study. BMC Med. 2020;18:178.
7. Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron- Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020;323:432- 43.
8. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3:e124486.
9. World Health Organization, Worldwide Prevalance of Anemia 1993- 2005. WHO Global Database on Anaemia. Switzerland: World Health Organization; 2008.
10. Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013;87:98-104.
11. World Health Organization, International statistical classification of diseases and related health problems. - 10th revision, World Health Organization Geneva, Switzerland: 2016.
12. Cançado RD, Muñoz M. Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter. 2011;33:461-9.
13. Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 2014;5:48-60.
14. Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, et al. Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review. Ther Clin Risk Manag. 2020;16:245-59.
15. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675.
16. Hanudel MR, Laster M, Salusky IB. Non-renal-Related Mechanisms of FGF23 Pathophysiology. Curr Osteoporos Rep. 2018;16:724-9.
17. Imel EA, Liu Z, McQueen AK, Acton D, Acton A, Padgett LR, et al. Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone. 2016;86:98-105.
18. Ifie E, Oyibo SO, Joshi H, Akintade O. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabetes Metab Case Rep. 2019;2019:19-0065.
19. Callejas-Moraga EL, Casado E, Gomez-Nuñez M, Caresia-Aroztegui AP. Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome. Bone Rep. 2020;13:100712.
20. Fang W, McMahon LP, Bloom S, Garg M. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose. JGH Open. 2019;3:438-40.